Navidea Biopharmaceuticals is tracking down cancer with targeting agents. The biopharmaceutical company specializes in diagnostics, therapeutics, and radiopharmaceutical agents. It has several radiopharmaceutical products in development designed to help surgeons detect disease. The firm's targeted products and platforms include Manocept and NAV4694. Its Lymphoseek product, part of the Manocept platform, gained FDA approval in 2013 (and European approval in 2014) and is marketed in the US to detect cancerous tissues. Other candidates aim to detect cancer and neurological conditions including Parkinson's disease and Alzheimer's disease. Customers include diagnostic laboratories, physicians, and patients.